Cargando…

Patient considerations in the management of ulcerative colitis – role of vedolizumab

Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6–24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kothari, Megha, Mudireddy, Prashant, Swaminath, Arun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548764/ https://www.ncbi.nlm.nih.gov/pubmed/26316768 http://dx.doi.org/10.2147/TCRM.S65650

Ejemplares similares

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
por: Dart, Robin J, et al.
Publicado: (2017)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
por: Schäffler, Holger, et al.
Publicado: (2017)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review
por: Bhandari, Renu, et al.
Publicado: (2021)

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
por: Takatsu, Noritaka, et al.
Publicado: (2020)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
por: Wilson, Michele R, et al.
Publicado: (2017)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab
por: Yan, Jing, et al.
Publicado: (2023)

Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
por: Hirsch, Ayal, et al.
Publicado: (2015)

A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
por: Kobayashi, Kiyonori, et al.
Publicado: (2018)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis
por: Zhu, Wanwan, et al.
Publicado: (2022)

Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
por: Miyazaki, Haruka, et al.
Publicado: (2023)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
por: Ooi, Choon Jin, et al.
Publicado: (2021)

Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
por: Bamias, Giorgos, et al.
Publicado: (2021)

Low immunogenicity of vedolizumab determined by a simple drug-tolerant assay in patients with ulcerative colitis
por: Yamashita, Noriaki, et al.
Publicado: (2022)

Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
por: Zhang, Jie, et al.
Publicado: (2022)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

A rare case of epiploic appendagitis in a patient affected by ulcerative colitis on vedolizumab therapy
por: Pugliese, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u67hs8f7c0819lsk23sn4g5m13